GSK's linerixibat shows promise for severe itch in rare liver disease

9 May 2025

UK pharma major GSK (LSE: GSK) has unveiled full Phase III data showing its experimental drug linerixibat significantly reduced itching in people with primary biliary cholangitis (PBC), a rare autoimmune liver disorder. The results were presented at this year’s European Association for the Study of the Liver (EASL) meeting.

The late-stage trial, known as GLISTEN, involved 238 adults with moderate-to-severe cholestatic pruritus — an intense internal itching — and met its primary goal, with patients on linerixibat reporting a notable drop in itch severity over 24 weeks compared to placebo.

Linerixibat users recorded an average placebo-adjusted improvement of 0.72 points on a 10-point itch scale. Key secondary outcomes also hit the mark, with over half of those on the drug benefitting from a clinically meaningful improvement.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Company News Directory

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical